Performance-enhancing product safety depends on actual contents, not just packaging promises. Muscle-building and weight-loss marketing can involve steroids, other hormonal agents, stimulants, or nutritional supplements. Some supplements studied have contained unlisted drug ingredients, so a familiar ingredient or reassuring category name cannot establish the full exposure.
You may recognize one ingredient on a carton without knowing how the complete product relates to medicines or hormones. That uncertainty is different from knowing the risks of an identified substance. The broader explanation of anabolic steroid side effects and health safety addresses non-prescribed steroid use; the narrower concern here is identifying what an appearance or performance product represents. The principles behind checking online health claims also matter, but a persuasive claim and a verified account of a product's contents are separate kinds of information.
Written by Tim Francis, SUD Content Specialist.
Tim is a nonclinical author. This guide supports discussion with qualified professionals.
What does appearance- and performance-enhancing product safety involve?
Appearance- and performance-enhancing product safety involves distinguishing advertised goals, substance categories, actual ingredients, and medical effects. Understanding non-prescribed anabolic steroid risks helps with one category, while evaluating health claims helps explain why a promise about muscle, leanness, or energy does not verify a product's complete contents.
The National Institute on Drug Abuse, or NIDA, uses appearance and performance enhancing drugs, abbreviated APEDs, as a broad term. Anabolic-androgenic steroids are the best-studied class, but they are not the entire category. NIDA also discusses other hormonal agents, products used to promote leanness, and nutritional supplements used alongside APEDs. Sharing a marketing goal does not make these substances chemically or medically interchangeable.
Four separate ideas can otherwise become blurred:
- The advertised goal is not the ingredient identity.
- The product category is not a complete contents analysis.
- A listed ingredient does not rule out unlisted ingredients.
- A reported effect does not identify its cause.
This distinction keeps concern proportionate. An unknown is not proof of contamination, but it also cannot serve as evidence of safety. NIDA's APED overview supports separating these questions rather than treating all performance products as one substance.
How do anabolic steroids differ from other hormonal and thermogenic products?
Anabolic steroids are testosterone-like substances, while other hormonal agents and thermogenic products involve different biological actions or intended effects. The distinction matters for understanding anabolic steroid exposure and for keeping medication concerns connected to professional care. Neither a shared appearance goal nor the word hormone makes these categories equivalent.
NIDA defines anabolic-androgenic steroids as synthetic substances similar to testosterone. Their anabolic effects concern skeletal muscle growth; their androgenic effects concern male sexual characteristics. Other agents discussed in performance enhancement include insulin, insulin-like growth factor, and human growth hormone. These have legitimate medical uses, but they are not anabolic-androgenic steroids.
Thermogenic products are discussed in relation to decreasing body fat or promoting leanness. NIDA includes xanthines such as caffeine, sympathomimetic drugs that resemble certain natural signaling chemicals, and thyroid hormones. The categories can overlap: a thyroid hormone is hormonal, yet NIDA also places it within this discussion of thermogenic agents.
| Category | NIDA's description or examples | What the category does not establish |
|---|---|---|
| Anabolic-androgenic steroids | Testosterone-like substances with anabolic and androgenic effects. | That another muscle-building product contains the same substance. |
| Other anabolic hormonal agents | Insulin, insulin-like growth factor, and human growth hormone. | That legitimate medical use establishes safety for performance use. |
| Thermogenic agents | Xanthines, sympathomimetics, and thyroid hormones discussed in relation to leanness. | That a weight-loss claim identifies the active substance. |
| Nutritional supplements | Products such as creatine or protein supplements used in performance settings. | That the category confirms the absence of unlisted drugs. |
This is a classification comparison, not a recommendation or safety ranking. The definitions come from NIDA's explanation of APED categories. A substance's identity, the reason for its use, and the evidence supporting that use remain separate considerations.
Why aren't nutritional supplements evaluated in the same way as FDA-approved medicines?
Nutritional supplements do not undergo the same preapproval requirements and quality tests as FDA-approved medicines, according to NIDA. This difference matters when assessing a product's health claims or considering questions about medicines in outpatient care. A supplement's availability does not establish that it passed the medicine-approval process.
The comparison concerns how evidence and product evaluation are established. It does not mean that every supplement is harmful, or that every approved medicine is appropriate for every person. It means you cannot assume that products presented in similar packaging have received the same kind of evaluation.
A medical use also belongs to an identified substance and purpose. NIDA describes legitimate medical uses for testosterone-like substances and other hormones. Those uses do not transfer automatically to a separately marketed muscle-building or fat-loss product. A claim that a supplement works like a medicine is still a claim, not evidence that the supplement has the medicine's identity or approval.
For example, advertising might compare a product with a prescription treatment. That comparison alone supplies no confirmation of complete ingredients, medical suitability, or equivalent effects. NIDA specifically identifies claims of alternatives to approved drugs or prescription-like effects as reasons for caution.
The useful distinction is between evidence about a named ingredient and evidence about the actual marketed product. Knowing something about the former does not settle the latter. This remains true even when the ingredient name sounds scientific or familiar.
What does research show about hidden drug ingredients in performance products?
Research summarized by NIDA has found unlisted prohormones, anabolic steroids, and other drug ingredients in some supplements. These findings connect steroid-related health concerns with the limits of trusting product claims. They demonstrate that undisclosed exposure can occur, without establishing the contents of every product currently sold.
NIDA describes a study of 634 nutritional supplements from 13 countries. In that sample, 15 percent contained some type of prohormone that was not listed on the label. Prohormones are hormone precursors. In this context, the concern is exposure to a substance connected with hormone production rather than only the nutritional ingredients a person expected.
The same NIDA overview of supplement research reports findings of anabolic steroids in supplements and drug ingredients in some products advertised for weight loss. The product's stated purpose therefore did not reliably identify every substance present in those studied products.
The limits of the finding matter as much as the number. Fifteen percent describes that particular study sample. It is not a current estimate for all supplements, a probability for an individual purchase, or proof about an untested brand. The study included products from multiple countries, and it should not be recast as a measurement of today's local retail market.
Detecting an undeclared ingredient also answers a different question from measuring health effects. It establishes that the substance was found in the tested material. That result alone does not establish how every person would respond or explain every symptom reported after use. It also does not, by itself, establish why the ingredient was present.
Why can't marketing claims or a familiar ingredient establish a product's complete contents?
Marketing claims describe promised benefits, while a familiar ingredient identifies only one declared component. Neither establishes everything present. The distinction behind checking health information also applies to product identity, and medication-related concerns remain relevant when a supplement's advertised effects resemble those of a drug.
Caffeine illustrates the difference without identifying any particular product as unsafe. NIDA lists caffeine among xanthines discussed in performance-enhancement settings. Recognizing that name may explain one declared component, but it cannot independently confirm that nothing else is present. Research about hidden ingredients makes that limitation concrete.
A claim such as legal alternative to anabolic steroids presents a different problem. It invites a conclusion about acceptability or reassurance without supplying verified contents. NIDA includes this type of claim among reasons consumers should be wary. Describing the claim here does not determine any product's current legal status.
These distinctions help prevent several unsupported conclusions:
- Familiar does not mean complete.
- Supplement does not mean evaluated like an approved medicine.
- Prescription-like does not mean prescription-approved.
- A legal-alternative claim does not establish medical safety.
None of those limits proves that a specific advertised product contains a hidden drug. They explain why the advertising cannot resolve the uncertainty. Even accurate information about one ingredient cannot substitute for evidence about the full product. NIDA's product warnings and documented label discrepancies support that narrower, more useful conclusion.
How do uncertain product contents complicate assessment of health effects?
Uncertain contents make it harder to connect an exposure with a health effect because the substance involved may not be fully identified. Medication-focused discussion and an understanding of known anabolic steroid risks can provide context, but neither a label nor a symptom alone establishes what caused a change.
Several uncertainties can coexist. A label may provide incomplete exposure information. A person may also be using prescribed medicines or other substances. NIDA notes that use of multiple APEDs and other drugs complicates interpretation of steroid-related research. This does not mean that health effects are unknowable; it means conclusions need to match the available evidence.
For example, a change that begins after a product is introduced establishes a sequence in time. It does not, on its own, identify an undeclared ingredient or prove that a particular component caused the change. Conversely, uncertainty about contents does not make a new health concern unimportant. Medical assessment can address the concern without first assuming a diagnosis from the marketing category.
Suspected non-prescribed exposure also must not be confused with prescribed hormone treatment. Findings about mislabeled products do not justify changing a prescribed medicine without medical guidance. Legitimate treatment involves a different clinical context from using an unidentified product for appearance or performance.
For severe symptoms or immediate danger, call 911. For suspected poisoning, Poison Control is available at 1-800-222-1222. These resources are listed in NIDA's treatment information.
If continued substance use despite harm is also a concern, recovery care addresses a related but distinct need. NIDA describes substance use disorders as treatable conditions. Such care complements medical assessment; it does not identify unknown product ingredients or replace evaluation of physical health effects.
Frequently asked questions
Are all appearance- and performance-enhancing products anabolic steroids?
No. NIDA describes anabolic-androgenic steroids as one class within a broader group. Other substances discussed include non-steroidal hormonal agents, thermogenic agents, and nutritional supplements used in performance settings. Similar goals, such as muscle growth or leanness, do not make these substances chemically equivalent or establish the contents of a particular product.
Can a product marketed as a supplement contain an unlisted prohormone or steroid?
Yes. NIDA summarizes research finding unlisted prohormones or anabolic steroids in some nutritional supplements. That establishes that undeclared exposure can occur. It does not prove that every supplement contains these substances, identify the contents of an untested product, or establish the current frequency of hidden ingredients throughout the market.
Does a legal-alternative claim establish that a performance product is safe?
No. A legal-alternative claim is marketing language, not confirmation of complete contents or medical safety. NIDA identifies claims of legal alternatives to anabolic steroids as reasons for caution. The claim also cannot establish that the product underwent the same preapproval requirements and quality tests as an FDA-approved medicine.
Does finding an ingredient in one study establish how common it is in every current product?
No. A study's findings describe the products examined within that research. NIDA's example involving 634 supplements from 13 countries cannot be treated as a current estimate for every supplement or an individual purchase. Evidence of a possible problem and evidence of its present market-wide frequency answer different questions.
Does this information justify changing prescribed hormone treatment without medical guidance?
No. Research about non-prescribed performance products and undisclosed ingredients does not determine the appropriateness of your prescribed treatment. NIDA distinguishes legitimate medical uses of hormones from performance-related misuse. Concerns about a prescription belong in a discussion with the prescribing professional, rather than a self-directed change based on supplement marketing or general research.
Sources
- National Institute on Drug Abuse: Anabolic Steroids and Other Appearance and Performance Enhancing Drugs
- National Institute on Drug Abuse: Treatment
- Choice Recovery Path: Intensive Outpatient Program (IOP)
- Choice Recovery Path: Contact information and outpatient access
If you or a loved one also wants help with substance use, you can review Choice's Intensive Outpatient Program (IOP), which includes weekly group and individual therapy, or contact Choice to discuss current outpatient options. You do not need to know which service fits before beginning that conversation.

